After being awarded a $5.1 million fee from More Pharma one month ago, shares of Microcyn® technology developer Oculus Innovative Sciences, Inc. (OCLS) should see another pop in it’s penny stock today now that they actually received it. Gaining as much as 35.14% since our initial alert three months ago at 0.74, OCLS stock has traded as high as $1 when the announcement made headlines on August 9th for the exclusive licensing of their Microcyn-based human healthcare products in Mexico, South/Central America and the Caribbean.
Our New Alert Is Set For Mid-September! Click HERE To Make Sure You Don’t Miss It!
OCLS Stock Chart
Market Cap: 30.60M
Close: 0.94, up 0.05 (5.62%)
Average Trade Size: 502
Issued and Outstanding: 32,553,662
Looking for Hot Penny Stocks?
Click here and get Alerts on the Best Penny Stocks FREE
The $5.1 million fee received is $1.5 million more than Oculus booked in revenues for the entire three month period ended June 30, 2012. Having reported Net Income of $325,000 fr that period, it is a safe assumption that Q3 is going to be a bang up quarter for the biotech small cap.
As per the terms of the deal with More Pharma, Oculus retains all proprietary rights to their products and intend for the license to be exercised exclusively by More Pharma and/or permitted sublicensees for the marketing and sale of the Company’s products in accordance with applicable label claims. More Pharma may not grant any sublicenses under the agreement without prior notification to Oculus and their subsequent approval of the sublicense.
With licensing rights and More Pharma as their exclusive distributor to South & Central America as well as the Caribbean less Cuba, Oculus can expect long-term revenue growth out of Mexico and Latin America while reducing their SG&A expenses by roughly $3 million annually in the short term.
About OCLS Stock
Oculus Innovative Sciences, Inc. is a commercial healthcare company that designs, produces, and markets innovative, safe and effective drugs, devices, and nutritional products. It is pioneering innovative products for the dermatology, surgical, wound care, and animal healthcare markets.
The Company’s primary focus is on its proprietary technology platform called Microcyn® Technology. This technology is based on electrically charged oxychlorine small molecules designed to target a wide range of organisms that cause disease (pathogens). Several Microcyn® Technology tissue care products are designed to treat infections and enhance healing while reducing the need for antibiotics.
Bottom Line: With only 32.55 million shares outstanding and trading just under the required level for NASDAQ minimum price compliance, OCLS is one small-cap penny stock long-term investors should look into. Net Income people. Net Income. When was the last time you read about a biotech penny stock that had net income?
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)Share